Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Drug company (FDA labeler)

West-Ward Pharmaceuticals Corp

NDC labeler code: 0143

What is a labeler?

The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.

Official FDA data only

Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.

Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.

At a glance

10Products (NDC)

Prescription medicines

FDA applications for these products

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
ApprovedApplicationMedicineSponsor
November 18, 2014NDA205917 Paricalcitol
PARICALCITOL
Hikma Pharms
February 13, 2013ANDA200219 Oxytocin
OXYTOCIN
Hikma Farmaceutica
December 2, 2009ANDA078765 Fosphenytoin sodium
FOSPHENYTOIN SODIUM
Hikma Farmaceutica
July 24, 2008NDA022276 Nicardipine
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Hikma Intl Pharms
December 26, 2006ANDA076780 Ondansetron
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE
Hikma Farmaceutica
December 26, 2006ANDA076781 Ondansetron
ONDANSETRON HYDROCHLORIDE
Hikma Farmaceutica

The sponsor is the company that holds the FDA application; it can differ from the labeler.

Recall timeline

2026

  1. June 10, 2026 · Class II · Ongoing · D-0714-2026 · Gemcitabine

    Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.

    Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hik

2024

  1. July 8, 2024 · Class I · Ongoing · D-0635-2024 · Acetaminophen

    Labeling: Label Mix-up: a bag of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection was found inside an overwrap labeled Acetaminophen Injection 1,000 mg per 100 mL (10 mg/mL)

    Acetaminophen Injection, 1,000 mg per 100 mL (10 mg/mL), 100 mL Single Dose bags, For Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica (Portugal), SA, distributed by Hikma Pharmaceuticals USA Inc Berkel

2022

  1. December 16, 2022 · Class II · Terminated · D-0090-2023 · Ganciclovir

    Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.

    Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: THYMOORGAN PHARMAZIE GmbH, Germany, Distributed by Hikma Berkeley Heights, NJ 07922, NDC 0143-9299-01

2021

  1. August 5, 2021 · Class III · Terminated · D-0771-2021 · Bleomycin

    Labeling: Not elsewhere classified: Mislabeling

    Bleomycin for Injection, USP, packaged in 15 units per single dose vial, Rx only, Manufactured by Thymoorgan Pharmazie GmbH Schiffgraben 23, 38690 Gosfar, Germany Distributed by Hikma USA Inc. Berkeley Heights, NJ 07922,

  2. March 15, 2021 · Class II · Terminated · D-0494-2021 · Levofloxacin

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

    Levofloxacin Injection in 5% Dextrose 500 mg in 100 mL 5% Dextrose (5 mg/mL) 24x100 mL Single Dose Flexible Containers NDC 0143-9721-24 West-Ward Pharmaceutical Corp Eatontown, NJ 07724 USA

2020

  1. August 14, 2020 · Class II · Terminated · D-1533-2020 · Buprenorphine

    Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.

    Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA I

  2. June 11, 2020 · Class II · Terminated · D-1309-2020 · Irinotecan hydrochloride

    Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.

    Irinotecan HCL Injection, USP, 100mg/5mL, 5 mL vials, Rx only, Manufactured by: Thymoorgan Pharmazie GmbH, Shiffgraben 23, 38690 Golsar, Germany Distributed by: West-Word Pharmaceutical Corp. Eatontown, NJ 07724 USA, NDC

  3. June 11, 2020 · Class II · Terminated · D-1308-2020 · Irinotecan hydrochloride

    Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.

    Irinotecan HCL Injection, USP, 100mg/5mL, 5 mL vials, Rx only, Manufactured by: Thymoorgan Pharmazie GmbH, Shiffgraben 23, 38690 Golsar, Germany Distributed by: West-Word Pharmaceutical Corp. Eatontown, NJ 07724 USA, NDC

  4. May 13, 2020 · Class II · Terminated · D-1274-2020 · Doxycycline

    Failed dissolution specification: The dissolution test at the 24 month time point (end of shelf life) yielded an out of specification result.

    Doxycycline Hyclate Tablets USP, 100 mg, packaged in a) 50-count bottle (NDC 0143-2112-50), b) 500-count bottle (NDC 0143-2112-05), Rx only, Mfd. by: West-Ward Pharmaceuticals Corp., Eatontown, NJ 07724.

  5. January 14, 2020 · Class III · Terminated · D-0801-2020 · Methylprednisolone

    Labeling: Incorrect Instructions: Vial label incorrectly instructs healthcare professional to reconstitute product with 16 mL rather than the correct volume of 8 mL of Bacteriostatic Water for Injection with Benzyl Alcohol.

    methylPREDNISolone Sodium Succinate For Injection, USP, 500 mg*/vial, Rx Only, Mfd by: HIKMA FARMACEUTICA (PORTUGAL), SA; Dist by: WEST-WARD, Eatontown, NJ 07724, NDC 0143-9850-01.

Show the 10 older recalls

2018

  1. July 24, 2018 · Class II · Terminated · D-1025-2018 · Doxycycline

    Failed Dissolution Specifications:

    Doxycycline Hyclate Tablets, USP, 100 mg*. 500-count bottle, Rx only. Manufactured by: West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724. NDC# 0143-2112-05.

  2. July 24, 2018 · Class II · Terminated · D-1024-2018 · Doxycycline

    Failed Dissolution Specifications:

    Doxycycline Hyclate Tablets, USP, 100 mg*. 50-count bottle, Rx only. Manufactured by: West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724. NDC# 0143-2112-50.

2016

  1. November 17, 2016 · Class III · Terminated · D-0172-2017 · Sodium ferric gluconate complex in sucrose

    Subpotent Drug: Product has an an out of specification in iron assay analysis found during 18 month stability testing.

    SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE INJECTION, 62.5mg elemental iron/5mL, 10 (5mL vials) per shelf pack, Rx only, Mfd: Hikma Farmaceutica (Portugal,) SA Distributed by: Westward Eatowntown NJ 07724 USA, Shelf pack

  2. November 4, 2016 · Class III · Terminated · D-0147-2017 · Amoxicillin

    Labeling: Label Error on Declared Strength: Some bottles miss a color coded panel where the strength of the product is typically displayed.

    Amoxicillin for Oral suspension, USP 400 mg/5 mL, 100 mL (when reconstituted), Rx only, Manufactured by: Hikma Pharmaceuticals, P.O. Box 183400, Amman 11118 - Jordan, NDC 0143-9887-01

2013

  1. September 23, 2013 · Class II · Terminated · D-66447-002 · Irinotecan hydrochloride

    Superpotent Drug: a recent review of the USP revealed that an incorrect calculation was used to determine the amount of irinotecan to use in formulation which will result in an assay higher than the labeled claim.

    Irinotecan Hydrochloride Injection, 100 mg/5 mL (20 mg/mL), 1 x 5 mL Single Dose Vial per carton, Rx only, Manufactured by: Thymoorgan Pharmazie GmbH, Schiffgraben 23, 38690 Vienenburg, Germany; Distributed by: West-Ward

  2. September 23, 2013 · Class II · Terminated · D-66447-001 · Irinotecan hydrochloride

    Superpotent Drug: a recent review of the USP revealed that an incorrect calculation was used to determine the amount of irinotecan to use in formulation which will result in an assay higher than the labeled claim.

    Irinotecan Hydrochloride Injection, 40 mg/2 mL (20 mg/mL), 1 x 2 mL Single Dose Vial per carton, Rx only, Manufactured by: Thymoorgan Pharmazie GmbH, Schiffgraben 23, 38690 Vienenburg, Germany; Distributed by: West-Ward

  3. May 13, 2013 · Class III · Terminated · D-691-2013 · Nicardipine

    Failed Impurity/Degradation Specifications; out of specification value for impurity Nitrophenylpuridine Derivative (NPP-D)

    Nicardipine Hydrochloride Injection 25 mg/10 mL (2.5 mg/mL), 10 mL single-use vials, Rx Only, Mfd. by Exela Pharma Sciences, LLC, Lenoir, NC, Dist. by: West-ward Pharmaceutical Corp., Eatontown, NJ --- NDC 0143-9689-10

  4. February 6, 2013 · Class II · Terminated · D-220-2013 · Ciprofloxacin

    Presence of Foreign Substance(s): A complaint was received for a rubber-like material in a 500 mg Ciprofloxacin tablet.

    Ciprofloxacin Tablets USP, 500 mg, 100-count bottle, Rx only, Manufactured for West-ward Pharmaceutical Corp., Eatowntown, NJ 07724 by Hikma Pharmaceuticals, Amman, Jordan, NDC 0143-9928-01

2012

  1. April 13, 2012 · Class II · Terminated · D-1437-2012 · Fosphenytoin sodium

    Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.

    Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By:

  2. April 13, 2012 · Class II · Terminated · D-1438-2012 · Fosphenytoin sodium

    Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.

    Fosphenytoin Sodium Injection, USP, 500 mg PE per 10 mL (50 mg PE per mL), 10 mL Single Dose Vial, packaged in 10-count x 10 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. B

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026

FDA Enforcement Report search → · Report an error →